1. Introduction {#sec1-ijms-18-02540}
===============

The most exciting event in the past five years within anti-cancer battle field is the emergence of immune checkpoint therapy, which now cuts a clear path out and joins the battle array of surgery, radiation, chemotherapy, and targeted therapy as a strong enforcement of cancer therapy. Immuno checkpoint molecules such as cytotoxic T lymphocyte-associated antigen-4 (CTLA-4, CD152) and programmed cell death protein 1 (PD-1) are membrane proteins residing on T lymphocytes and deliver negative signals to limit T lymphocyte mediated immune responses. These checkpoint molecules belong to a family of cell signaling molecules named co-stimulatory molecules that regulates T lymphocyte functions positively or negatively along with T cell receptors. PD-1/Programmed death-ligand (PD-L) pathway consists of PD-1 and its two ligands. PD-1 is inducibly expressed on T cells, B cells, Natural Killer T cells (NKT cells), and monocytes upon activation. Programmed death-ligand 1 (PD-L1) is expressed on antigen presenting cells (B cells, dendritic cells, macrophages), cultured bone marrow derived mast cells and T cells. PD-L1 is also expressed on non-hematopoietic cells such as astrocytes, pancreatic islet cells, keratinocytes and vascular endothelial cells, etc. The program death-ligand 2 (PD-L2) is only expressed inducibly on dendritic cells (DCs), macrophages, and bone marrow derived cultured mast cells. Under normal physiological conditions, PD-L1 mRNA was found expressed broadly in various tissues, but PD-L1 protein is only found on a few tissues such as tonsil, a small fraction of macrophage-like cells in lung and liver, and placenta, suggesting PD-L1 mRNA is tightly regulated by post-transcriptional machinery \[[@B1-ijms-18-02540],[@B2-ijms-18-02540]\]. In contrast, PD-L1 protein was found expressed on various human cancer cells. Although many cytokines are indicated to play roles in inducing or maintaining PD-L1 expression, both in vitro and in vivo studies have proved that expression of PD-L1 protein in antigen presenting cells (APCs), regulatory T lymphocytes, and cancer cells strongly relied on the existence of interferon-gamma (IFN-γ). Inflammatory cells, especially activated T lymphocytes are usually considered the major source of IFN-γ. It is proposed that PD-L1 is up-regulated in response to inflammation and suppresses excessive immune responses which may cause unnecessary tissue injury. Tumor cells that arise from normal cells adopt this mechanism to evade tumor immunity \[[@B3-ijms-18-02540],[@B4-ijms-18-02540]\].

Several signaling pathways were reported to be involved in the regulation of PD-L1 in multiple types of tumors. The two major signaling pathways are Just Another Kinase (JAK)/Signal transducers and activators of transcription (STAT)/phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/methyl ethyl ketone (MEK)/extracellular regulated protein kinases (ERK) and JAK/src homology 2-containing tyrosine phosphatase (SHP2)/rat sarcoma (RAS)/rapidly accelerated fibrosarcoma (RAF)/MEK/ERK pathways. Clearly the MEK/ERK kinases involved in both pathways possess critical roles for IFN-γ induced expression of PD-L1. For example, PD-L1 expression induced by IFN-γ was found blocked by inhibition of MEK/ERK pathway using U0126 (inhibitor of MEK1/2) in multiple myeloma (MM) plasma cells and hepatic stellate cells (HSCs) \[[@B5-ijms-18-02540],[@B6-ijms-18-02540]\].

PD-L1 was also regulated by phosphatase and tensin homolog deleted on chromosome ten (PTEN)/PI3K/AKT/mammalian target of rapamycin (mTOR) pathway. Loss of PTEN promoted cell proliferation, cell invasion and significant increase in the levels of phospho-AKT and phospho-mTOR, resulting in enhanced protein translation of PD-L1 in human glioma \[[@B7-ijms-18-02540]\]. In addition, interferon regulatory factor 1 (IRF1) is a downstream target of STAT1and the critical transcription factor for PD-L1 expression. Knockdown of IRF1 using siRNA greatly decreased both the constitutive and IFN-γ-induced expression of PD-L1 inA549 cells \[[@B8-ijms-18-02540]\]. Moreover, it can be speculated that IFN-γ receptor (IFNGR) modulating the expression and activation of various signaling molecules mentioned above are probably also involved in the regulation of PD-L1 expression.

Analysis of human gene transcriptome shows that only 1 to 2 percent of genome sequences have protein-coding capacity, suggesting that there may be a large number of non-coding RNAs \[[@B9-ijms-18-02540]\]. MicroRNAs are small non-coding RNAs consisting of 20--22 nucleotides involved in crucial biological processes including development, differentiation, apoptosis and proliferation \[[@B10-ijms-18-02540]\]. The action mechanism of microRNAs is a multistep process. The genes encoding microRNAs in the nucleus are transcribed into pri-microRNAs which were cut into pre-microRNAs by DroshaRNase \[[@B11-ijms-18-02540]\]. Under the participation of Ras-related nuclear protein and exportin-5, pre-microRNAs were transported into the cytoplasm to be processed into mature microRNAs by Dicer RNase \[[@B12-ijms-18-02540],[@B13-ijms-18-02540]\]. After processing, the double helix of mature microRNA unwinds and one strand is bound to an RNA-induced silencing complex (RISC) to form an asymmetric RISC assembly. Then the complex binds to the target mRNA. MicroRNA is able to couple with its complementary mRNA, leading to degradation of the coupled mRNA. When microRNA and target mRNA are not fully complementary, microRNA is combined with the 3′-UTR of target mRNA and inhibits the protein translation of the mRNA \[[@B14-ijms-18-02540],[@B15-ijms-18-02540]\]. In the past decades, multiple microRNAs have been found to play important roles in cancer and regulate PD-L1 directly or indirectly ([Figure 1](#ijms-18-02540-f001){ref-type="fig"} and [Table 1](#ijms-18-02540-t001){ref-type="table"}) \[[@B16-ijms-18-02540]\]. In this review, we focus on the relationship between the PD-1/PD-L1 pathway and microRNA.

2. Current Knowledge on MicroRNAs Involved in PD-1/PD-L1 Regulation {#sec2-ijms-18-02540}
===================================================================

Some microRNAs have been found to directly target the 3′-UTR of PD-1 or PD-L1 mRNA. Some microRNAs may regulate PD-1/PD-L1 indirectly via signaling molecules such as PTEN, IFR-1, and so on. In this section, we will discuss these two groups of microRNAs separately.

2.1. MicroRNAs That Regulate PD-1/PD-L1 Directly {#sec2dot1-ijms-18-02540}
------------------------------------------------

### 2.1.1. MicroRNAs Regulating PD-1 Expression {#sec2dot1dot1-ijms-18-02540}

Results from dual luciferase assays demonstrated that miR-28 could inhibit PD-1 through binding to its 3′-UTR. The expression of PD-1 was attenuated after transfection with miR-28 mimic in B16F10 cells. The ability of miR-28 in regulating T cell exhaustion was also evidenced by the fact that the expression of PD-1, T-cell immunoglobulin domain and mucin domain 3 (TIM3) and B- and T-lymphocyte attenuator (BTLA) of exhausted T cells was increased by the inhibitor of miR-28 \[[@B17-ijms-18-02540]\].

Target binding algorithms predicted that miR-138 could bind PD-1. Transfection of human CD4+ T cells with miR-138 suppressed PD-1 expression in vitro \[[@B18-ijms-18-02540]\]. Moreover, miR-4717 levels in patients with HBV infection were significantly reduced. The single-nucleotide polymorphisms (SNP) rs10204525 (+8669 G/A) in PD-1 gene was revealed to be associated with chronic Hepatitis B Virus (HBV) infection and located in the 3′UTR of PD-1 gene. MiR-4717 decreased PD-1 expression through binding with PD-1 rs10204525 polymorphic site and plays a role in the disease susceptibility of chronic HBV infection \[[@B19-ijms-18-02540]\].

### 2.1.2. MicroRNAs Regulating PD-L1 Expression {#sec2dot1dot2-ijms-18-02540}

Compared with PD-1, more microRNAs have been found to target PD-L1 using dual luciferase assay ([Table 1](#ijms-18-02540-t001){ref-type="table"}).

In addition to luciferase experiments, in argonaute 2 Immunoprecipitation (AGO2 IP) experiments, an interaction between the PD-L1 3′UTR and the miR-15a or miR-16 were also discovered. PD-L1 mRNA dropped in malignant pleural mesothelioma cell line (VMC23) after transfection with miR-15a, miR-15b or miR-16 mimic \[[@B20-ijms-18-02540]\]. Furthermore, an inverse correlation between PD-L1 and miR-34a expression in 44 acute myeloid leukemia (AML) samples was observed. Over-expression of miR-34a in HL-60 andKasumi-1 cells reduced the expression of PD-L1 \[[@B21-ijms-18-02540]\]. Besides, expression of PD-L1 was reduced in bulk cancer cells following treatment with miR-93-5p and miR-106b-5p mimics, respectively \[[@B22-ijms-18-02540]\]. To examine the effect of miR-138-5p on endogenous PD-L1 expression, two cell lines with low miR-138-5p expression, colorectal cancer cell lines (HCT116 and SW620), were transfected with miR-138-5p mimics. PD-L1 protein levels were decreased \[[@B23-ijms-18-02540]\]. RT-PCR and Western blot experiments also demonstrated that miR-142-5p can regulate PD-L1 expression by binding to its 3′UTR. Flow cytometry and RT-PCR experiments demonstrated that miR-142-5p overexpression on tumor cells inhibited the expression of PD-L1 in Panc02 cells \[[@B24-ijms-18-02540]\]. MiR-152 in human gastric cancer tissues was significantly lower than that in matched adjacent normal tissues. Furthermore, there was a marked correlation between the levels of miR-152 and PD-L1 mRNA in gastric cancer tissues, due to miR-152 directly bind to PD-L1 3′UTR and inhibited PD-L1 expression \[[@B25-ijms-18-02540]\]. Transfection with miR-193a-3p led to reduction in PD-L1 mRNA expression in VMC23 cells, the low levels of PD-L1 mRNA in H28 cells were further reduced by miR-193a-3p transfection \[[@B20-ijms-18-02540]\]. Inducible or transient miR-200 expression suppressed PD-L1 expression on human mesenchymal lung cancer cell lines H157, H1155, H1299, and H460 \[[@B26-ijms-18-02540]\]. Dendritic cells expressing miR-324-5p or miR-338-5p displayed reduced ability to induce the surface expression as well as total protein levels of PD-L1 on *M. bovis* BCG infection \[[@B27-ijms-18-02540]\]. MiR-424 regulates the PD-1/PD-L1 pathways in chemo resistant ovarian cancer through direct binding to PD-L1 3′UTR \[[@B28-ijms-18-02540]\]. The level of miR-513 was reduced in cells after exposure to *C. parvum* and increased the expression of PD-L1 \[[@B29-ijms-18-02540]\].

2.2. Potential PD-1/PD-L1 Regulatory microRNAs {#sec2dot2-ijms-18-02540}
----------------------------------------------

In the section, we outline the microRNAs that may affect PD-1/PD-L1 expression via regulation of the related signaling pathways such as IFN-γ/IFNGR/JAK/STAT/PI3K/AKT/MEK/ERK and so on.

### 2.2.1. MicroRNAs Regulating IFN-γ Expression {#sec2dot2dot1-ijms-18-02540}

The 3′UTR of the human IFN-γ gene is a perfect match for the miR-181a seed sequence. Co-transfection of a vector expressing miR-181a with the luciferase reporter vector containing the wide-type IFN-γ 3′UTR decreased the luciferase activity significantly. Overexpression of miR-181a had no significant effect on the luciferase activity when the reporter contained the mutated 3′UTR of the IFN-γ gene, confirming IFN-γ is directly targeted by miR-181a \[[@B30-ijms-18-02540]\]. IFN-γ is also the target of miR-24-2 and miR-220c. In turn, IFN-γ can induce the expression of miR-24-2 and miR-220c \[[@B31-ijms-18-02540]\].

### 2.2.2. MicroRNAs Regulating IFNGR Expression {#sec2dot2dot2-ijms-18-02540}

The results of real-time PCR of miR-378 and Western blot analysis of the IFNGR1 protein at different stages of corpus luteum (CL) development showed that mir-378 decreased the expression of IFNGR1 protein but not IFNGR1 mRNA \[[@B32-ijms-18-02540]\], suggesting it may regulate IFNGR1 indirectly.

### 2.2.3. MicroRNAs Regulating STAT1 Expression {#sec2dot2dot3-ijms-18-02540}

STAT1 was directly regulated by miR-145 detected by luciferase assays \[[@B33-ijms-18-02540]\]. MiR-146a, one of the microRNAs prevalently expressed in Treg cells, was critical for their suppressor function. The deficiency of miR-146a in Treg cells resulted in a breakdown of immunological tolerance manifested in fatal IFN-γ-dependent immune-mediated lesions in a variety of organs. This was likely due to augmented expression and activation of STAT1, a direct target of miR-146a \[[@B34-ijms-18-02540]\]. MiR-150 and miR-223 target the STAT1 3′UTR, reduce STAT1 expression, and reduce both IFN-dependent and IFN-independent STAT1-mediated signaling \[[@B35-ijms-18-02540]\]. MiR-27a and miR-220c were regulated by STAT1. In the meanwhile, miR-27a and miR-220c can in turn target the 3′UTRs of STAT1 \[[@B31-ijms-18-02540]\]. Therefore, miR-200c may regulate PD-L1 expression by target IFN-γ and STAT1.

### 2.2.4. MicroRNAs Regulating IRF1 Expression {#sec2dot2dot4-ijms-18-02540}

Luciferase assays demonstrated that IRF1 was directly regulated by miR-23b and miR-383. MiR-23b over-expression significantly decreased IRF1 mRNA levels \[[@B36-ijms-18-02540]\]. Both IRF1 protein and IRF1 mRNA expressions were significantly decreased in miR-383-transfected NT2 (testicular embryonal carcinoma) cells \[[@B37-ijms-18-02540]\].

### 2.2.5. MicroRNAs Regulating PTEN Expression {#sec2dot2dot5-ijms-18-02540}

Like PD-L1, many microRNAs have been shown to inhibit PTEN expression by directly binding to PTEN 3′UTR ([Table 1](#ijms-18-02540-t001){ref-type="table"}).

MiR-10a was upregulated in non-small-cell lung carcinoma (NSCLC) compared with corresponding normal tissues. Furthermore, over-expression of miR-10a promoted NSCLC cell proliferation, migration and invasion, suggesting that miR-10a contributes to NSCLC by targeting PTEN \[[@B38-ijms-18-02540]\]. MiR-19a and miR-19b were upregulated in gastric cancer cells and decreased the sensitivity of gastric cancer cells to anticancer drugs by inhibiting the expression of PTEN \[[@B39-ijms-18-02540]\]. PTEN expression was inhibited by miR-20b and miR-21 through binding with the 3′UTR of PTEN mRNA in colorectal cancer (CRC), resulting in PD-L1 over-expression \[[@B40-ijms-18-02540]\]. MiR-26a reduced the expression level of PTEN in A549, SK-MES-1, and H661 cells. When miR-26a was knockdown in H661 cells, the expression level of PTEN increased \[[@B41-ijms-18-02540]\]. MiR-92a was over-expressed in colorectal cancer cell lines. Up-regulation of miR-92a decreased the expression of PTEN \[[@B42-ijms-18-02540]\]. MiR-106b has been shown to target PD-L1. Meanwhile, miR-106 had been found to inhibit PTEN through directly binding to its 3′UTR \[[@B43-ijms-18-02540]\]. MiR-205 could inhibit expression of PTEN by directly targeting the 3′UTR of PTEN gene in nasopharyngeal carcinoma (NPC) \[[@B44-ijms-18-02540]\]. MiR-214 induces cell survival through targeting the 3′UTR of the PTEN, which leads to down-regulation of PTEN protein and activation of AKT pathway \[[@B45-ijms-18-02540]\]. MiR-221 and miR-222 were discovered to induce cell growth and cell cycle progression via direct modulation of PTEN expression \[[@B46-ijms-18-02540]\]. Expression of miR-301a was markedly elevated in breast cancer. MiR-301a promoted breast cancer invasion via directly targeting the 3′UTR of PTEN gene and subsequent down-regulation of PTEN \[[@B47-ijms-18-02540]\]. MiR-494 in myeloid-derived suppressor cells (MDSCs) was up-regulated and played a critical role in promoting tumor growth and metastasis by combining to the 3′UTR of PTEN and inhibiting PTEN \[[@B48-ijms-18-02540]\].

### 2.2.6. MicroRNAs Regulatingm TOR Expression {#sec2dot2dot6-ijms-18-02540}

Four microRNAs (miR-100, miR-101, miR-199a-3p, and miR-497) have been found to inhibit mTOR by directly combining to its 3′UTR using luciferase assays.

MiR-100 could inhibit bladder cancer cell growth and colony formation by targeting mTOR \[[@B49-ijms-18-02540]\]. Overexpression of miR-101 significantly decreased the expression of mTOR at both mRNA and protein levels in Saos-2 cells \[[@B50-ijms-18-02540]\]. MiR-199a-3p could inhibit endometrioid adenocarcinoma (EEC) cell proliferation through binding to the 3′-UTR of mTOR \[[@B51-ijms-18-02540]\]. Low miR-497 expression levels were associated with chemo-resistant phonotype of ovarian cancer. MiR-497 could suppress mTOR protein expressions through the binding of mTOR 3′UTR. Downregulation of miR-497 contributed to high levels of mTOR \[[@B52-ijms-18-02540]\].

### 2.2.7. MicroRNAs Regulating Eukaryotic Translation Initiation Factor 4B (EIF4B) Expression {#sec2dot2dot7-ijms-18-02540}

EIF4B integrates the signals from the PI3K/AKT/mTOR pathway \[[@B62-ijms-18-02540]\] and is directly regulated by miR-150 and miR-216a. MiR-150 could suppress EIF4B protein expressions through binding to the 3′UTR of EIF4B. Downregulation of miR-497 contributed to high levels of EIF4B \[[@B53-ijms-18-02540]\]. Over-expression of miR-216a suppresses NSCLC cell growth, metastasis, and enhances cisplatin-induced cell growth inhibition and apoptosis by directly targeting EIF4B \[[@B54-ijms-18-02540]\].

### 2.2.8. MicroRNAs Regulating SHP2 Expression {#sec2dot2dot8-ijms-18-02540}

As with IFNGR, only one microRNA was reported to regulate SHP2 expression. MiR-204 could inhibit SHP2 via combining to the 3′UTR of SHP2 using luciferase assays \[[@B55-ijms-18-02540]\].

### 2.2.9. MicroRNAs Regulating c-Fos Protein (c-Fos) Expression {#sec2dot2dot9-ijms-18-02540}

Finally, six microRNAs (miR-101, miR-139-5p, miR-155, miR-181a, miR-181b, and miR-490-5p) have been shown that involved in the regulation of c-Fos.

MiR-101 was downregulated and acted as a tumor suppressor in osteosarcoma (OS) cells via targeting c-Fos \[[@B56-ijms-18-02540]\]. MiR-139-5p suppressed c-Fos transcription through binding to the 3′-UTR of c-Fos in primary biliary cholangitis \[[@B57-ijms-18-02540]\]. C-Fos mRNA levels were found to decrease in a manner that was closely correlated with increased miR-155 expression during the activation of human monocyte-derived DCs (Mo-DCs). MiR-155 regulates both the stability and translation of c-Fos mRNA \[[@B58-ijms-18-02540]\]. MiR-181a targeted the 3′-UTR of c-Fos, abundance of miR-181a reduced c-Fos protein, whereas inhibition of miR-181a increased c-Fos protein in bone marrow-derived DCs (BMDCs) \[[@B59-ijms-18-02540]\]. MiR-181b regulated FOS expression by directly targeting the binding site within the 3′-UTR in malignant gliomas \[[@B60-ijms-18-02540]\]. MiR-490-5p was downregulated in human bladder cancer tissue and cell lines compared to normal adjacent tissue and a non-malignant cell line. MiR-490-5p is a novel tumor suppressor of bladder cancer cell proliferation through targeting c-Fos \[[@B61-ijms-18-02540]\].

3. Conclusions {#sec3-ijms-18-02540}
==============

PD-1/PD-L1 immune checkpoint plays an important role in tumor immune escape and the formation of tumor microenvironment. MicroRNAs have shown a new avenue in the understanding of the molecular regulatory mechanisms involved in PD-1/PD-L1 signaling pathway. MicroRNAs are able to modulate multiple signaling pathways and regulatory networks. Even if the change of microRNAs expression is subtle, it may cause significant changes in PD-1/PD-L1 signaling pathway. Manipulation of PD-1/PD-L1 expression is not the only option for microRNAs to regulate PD-1/PD-L1 pathway. MicroRNAs regulating the transport or downstream targets of PD-1/PD-L1 may also have a significant impact on PD-1/PD-L1 pathway. For example, the PD-1downstream molecule Zeta-chain-associated protein kinase 70 (ZAP70) is regulated by miR-631 \[[@B63-ijms-18-02540]\]. In this review, we focused on these microRNAs regulating PD-1/PD-L1 expression and demonstrated that 49 microRNAs target the 3′-UTR of either PD-1/PD-L1 themselves or their upstream genes. Among them, five microRNA (miR-101, miR-106b, miR-181a, miR-150, and miR-200c) have two target mRNA. Currently little is known about the correlation between these microRNAs and the prognostic roles of PD-L1 or the therapeutic effects of the PD-1/PD-L1 antibodies. Significant advances have been made for employing microRNAs as useful diagnostic targets. It is possible that in addition for further understanding the molecular regulatory network of PD-1/PD-L1, these microRNAs can also be potential useful biomarkers for prognosis of PD-1/PD-L1 antibody treatment.
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ijms-18-02540-t001_Table 1

###### 

MicroRNAs involved in PD-1/PD-L1 signaling pathway and their respective target genes.

  Target mRNA   miRNA         Host             Reference
  ------------- ------------- ---------------- -------------------------------------------------
  **PD-1**      miR-28        melanoma         Li et al. \[[@B17-ijms-18-02540]\]
                miR-138       glioblastoma     Wei et al. \[[@B18-ijms-18-02540]\]
                miR-4717      HCC              Zhang et al. \[[@B19-ijms-18-02540]\]
  **PD-L1**     miR-15a       MPM              Kao et al. \[[@B20-ijms-18-02540]\]
                miR-15b       MPM              Kao et al. \[[@B20-ijms-18-02540]\]
                miR-16        MPM              Kao et al. \[[@B20-ijms-18-02540]\]
                miR-34a       AML              Wang et al. \[[@B21-ijms-18-02540]\]
                miR-93        MSC              Cioffi et al. \[[@B22-ijms-18-02540]\]
                miR-106b      MSC              Cioffi et al. \[[@B22-ijms-18-02540]\]
                miR-138-5p    CRC              Zhao et al. \[[@B23-ijms-18-02540]\]
                miR-142-5p    PC               Jia et al. \[[@B24-ijms-18-02540]\]
                miR-152       GC               Wang et al. \[[@B25-ijms-18-02540]\]
                miR-193a-3p   MPM              Kao et al. \[[@B20-ijms-18-02540]\]
                miR-200       GC               Chen et al. \[[@B26-ijms-18-02540]\]
                miR-324-5p    Treg             Holla et al. \[[@B27-ijms-18-02540]\]
                miR-338-5p    Treg             Holla et al. \[[@B27-ijms-18-02540]\]
                miR-424       OC               Xu et al. \[[@B28-ijms-18-02540]\]
                miR-513       Cholangiocytes   Gong et al. \[[@B29-ijms-18-02540]\]
  **IFN-γ**     miR-181a      aGVHD            Sang et al. \[[@B30-ijms-18-02540]\]
                miR-24-2      HeLa             Wang et al. \[[@B31-ijms-18-02540]\]
                miR-200c      HeLa             Wang et al. \[[@B31-ijms-18-02540]\]
  **IFNGR**     miR-378       CL               Ma et al. \[[@B32-ijms-18-02540]\]
  **STAT1**     miR-27a       HeLa             Wang et al. \[[@B31-ijms-18-02540]\]
                miR-145       CC               Gregersen et al. \[[@B33-ijms-18-02540]\]
                miR-146a      Treg             Lu et al. \[[@B34-ijms-18-02540]\]
                miR-150       ATL              Moles et al. \[[@B35-ijms-18-02540]\]
                miR-223       ATL              Moles et al. \[[@B35-ijms-18-02540]\]
                miR-200c      HeLa             Wang et al. \[[@B31-ijms-18-02540]\]
  **IRF1**      miR-23b       DF-1             Li et al. \[[@B36-ijms-18-02540]\]
                miR-383       TEC              Lian et al. \[[@B37-ijms-18-02540]\]
  **PTEN**      miR-10a       NSCLC            Yu et al. \[[@B38-ijms-18-02540]\]
                miR-19a       GC               Wang et al. \[[@B39-ijms-18-02540]\]
                miR-19b       GC               Wang et al. \[[@B39-ijms-18-02540]\]
                miR-20b       CRC              Zhu et al. \[[@B40-ijms-18-02540]\]
                miR-21        CRC              Zhu et al. \[[@B40-ijms-18-02540]\]
                miR-26a       LC               Liu et al. \[[@B41-ijms-18-02540]\]
                miR-92a       CRC              Zhang et al. \[[@B42-ijms-18-02540]\]
                miR-106b      GC               Yang et al. \[[@B43-ijms-18-02540]\]
                miR-205       NPC              Qu et al. \[[@B44-ijms-18-02540]\]
                miR-214       OC               Yang et al. \[[@B45-ijms-18-02540]\]
                miR-221       GC               Zhang et al. \[[@B46-ijms-18-02540]\]
                miR-222       GC               Zhang et al. \[[@B46-ijms-18-02540]\]
                miR-301a      BC               Ma et al. \[[@B47-ijms-18-02540]\]
                miR-494       MDSCs            Liu et al. \[[@B48-ijms-18-02540]\]
  **MTOR**      miR-100       BLC              Xu et al. \[[@B49-ijms-18-02540]\]
                miR-101       OTC              Lin et al. \[[@B50-ijms-18-02540]\]
                miR-199a-3p   EEC              Wu et al. \[[@B51-ijms-18-02540]\]
                miR-497       OC               Xu et al. \[[@B52-ijms-18-02540]\]
  **EIF4B**     miR-150       HSC              Fang et al. \[[@B53-ijms-18-02540]\]
                miR-216a      NSCLC            Wang et al. \[[@B54-ijms-18-02540]\]
  **SHP2**      miR-204       PASMCs           Courboulin et al. \[[@B55-ijms-18-02540]\]
  **FOS**       miR-101       OS               Wang et al. \[[@B56-ijms-18-02540]\]
                miR-139-5p    PBC              Katsumi1 et al. \[[@B57-ijms-18-02540]\]
                miR-155       DCs              Dunand-Sauthier et al. \[[@B58-ijms-18-02540]\]
                miR-181a      DCs              Wu et al. \[[@B59-ijms-18-02540]\]
                miR-181b      MG               Tao et al. \[[@B60-ijms-18-02540]\]
                miR-490-5p    BLC              Li et al. \[[@B61-ijms-18-02540]\]

aGVHD = Acute graft-versus-host; CL = corpus luteum; CC = colon cancer; Treg = Foxp3 + regulatory T Cell; ATL = adult T cell leukemia/lymphoma; TEC = testicular embryonal carcinoma; NSCLC = non-small cell lung cancer; GC = gastric cancer; CRC = colorectal cancer; LC = lung cancer; NPC = nasopharyngeal carcinoma; OC = ovarian cancer; BC = breast cancer; MDSCs = myeloid-derived suppressor cells; BLC = bladder cancer; OTC = osteosarcoma cells; EEC = endometrial cancer cell; HSC = hematopoietic stem cells; PASMCs = pulmonary artery smooth muscle cells; DCs = dendritic cell; MPM = malignant pleural mesothelioma; AML = acute myeloid leukemia; MSC = mesenchymal stem cells; PC = pancreatic cancer; HCC = hepatocellular carcinoma. OS = osteosarcoma; PBC = primary biliary cholangitis; MG = malignant gliomas.
